fenofibrate has been researched along with Kidney Failure, Chronic in 15 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report on a 26-year-old male who presented with fenofibrate-induced rhabdomyolysis with chronic renal failure due to nephrotic syndrome." | 7.78 | Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report. ( Begenik, H; Canbaz, ET; Emre, H; Erdur, FM; Erkoc, R; Soyoral, YU, 2012) |
| "Fenofibrate is a fibric acid derivative agent that is used in the treatment of hyperlipidaemia." | 5.38 | Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus. ( Begenik, H; Canbaz, ET; Emre, H; Erdur, MF; Erkoc, R; Soyoral, YU, 2012) |
| "In people with type 2 diabetes at high risk for cardiovascular disease, intensive glycemic control may result in a long-term reduction in macroalbuminuria; however, intensive BP control and fenofibrates may increase the risk for adverse kidney events." | 5.27 | Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. ( Buse, JB; Craven, TE; Ismail-Beigi, F; Katz, L; Mottl, AK; Mychaleckyj, JC; Papademetriou, V; Pedley, CF; Sigal, RJ; Simmons, DL, 2018) |
| "Fenofibrate is a potent hypolipemic agent, widely used in patients with mild to severe renal failure in whom hyperlipoproteinemia is frequent." | 5.09 | [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency]. ( Achard, JM; el Esper, N; Fournier, A; Hottelart, C; Pruna, A, 1999) |
| "We report on a 26-year-old male who presented with fenofibrate-induced rhabdomyolysis with chronic renal failure due to nephrotic syndrome." | 3.78 | Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report. ( Begenik, H; Canbaz, ET; Emre, H; Erdur, FM; Erkoc, R; Soyoral, YU, 2012) |
| "Fenofibrate treatment should not be contraindicated in moderate renal impairment, suggesting that current guidelines may be too restrictive." | 2.77 | Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. ( Celermajer, D; Davis, TM; Donoghoe, MW; Drury, PL; Hedley, J; Jenkins, AJ; Keech, AC; Lehto, S; Rajamani, K; Simes, RJ; Stanton, K; Ting, RD, 2012) |
| "Microalbuminuria is an early marker of diabetic nephropathy and an independent risk factor for cardiovascular disease." | 2.44 | Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. ( Brown, WV, 2008) |
| "Fenofibrate is a fibric acid derivative agent that is used in the treatment of hyperlipidaemia." | 1.38 | Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus. ( Begenik, H; Canbaz, ET; Emre, H; Erdur, MF; Erkoc, R; Soyoral, YU, 2012) |
| " Several studies have found that long-term use of LLDs is associated with an increased risk of gallstone disease (GSD) in the general population." | 1.37 | Long-term use of fenofibrate is associated with increased prevalence of gallstone disease among patients undergoing maintenance hemodialysis. ( Chang, CT; Hsu, WM; Huang, CC; Kuo, HL; Liang, CC; Lin, HH; Liu, YL; Wang, IK; Yeh, HC, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Yen, CL | 1 |
| Fan, PC | 1 |
| Lin, MS | 1 |
| Lee, CC | 1 |
| Tu, KH | 1 |
| Chen, CY | 1 |
| Hsiao, CC | 1 |
| Hsu, HH | 1 |
| Tian, YC | 1 |
| Chang, CH | 1 |
| Streja, E | 1 |
| Streja, DA | 1 |
| Soohoo, M | 1 |
| Kleine, CE | 1 |
| Hsiung, JT | 1 |
| Park, C | 1 |
| Moradi, H | 1 |
| Mottl, AK | 1 |
| Buse, JB | 1 |
| Ismail-Beigi, F | 1 |
| Sigal, RJ | 1 |
| Pedley, CF | 1 |
| Papademetriou, V | 1 |
| Simmons, DL | 1 |
| Katz, L | 1 |
| Mychaleckyj, JC | 1 |
| Craven, TE | 1 |
| Soyoral, YU | 2 |
| Canbaz, ET | 2 |
| Erdur, MF | 1 |
| Emre, H | 2 |
| Begenik, H | 2 |
| Erkoc, R | 2 |
| Hu, Z | 1 |
| Huang, S | 1 |
| Wu, Y | 1 |
| Liu, Y | 1 |
| Liu, X | 1 |
| Su, D | 1 |
| Tao, Y | 1 |
| Fu, P | 1 |
| Zhang, X | 1 |
| Peng, Z | 1 |
| Zhang, S | 1 |
| Yang, Y | 1 |
| Brown, WV | 1 |
| Liang, CC | 1 |
| Wang, IK | 1 |
| Kuo, HL | 1 |
| Yeh, HC | 1 |
| Lin, HH | 1 |
| Liu, YL | 1 |
| Hsu, WM | 1 |
| Huang, CC | 1 |
| Chang, CT | 1 |
| Erdur, FM | 1 |
| Ting, RD | 1 |
| Keech, AC | 1 |
| Drury, PL | 1 |
| Donoghoe, MW | 1 |
| Hedley, J | 1 |
| Jenkins, AJ | 1 |
| Davis, TM | 1 |
| Lehto, S | 1 |
| Celermajer, D | 1 |
| Simes, RJ | 1 |
| Rajamani, K | 1 |
| Stanton, K | 1 |
| Meas, T | 1 |
| Cimadevilla, C | 1 |
| Timsit, J | 1 |
| Mouly, S | 1 |
| Guillausseau, PJ | 1 |
| Desager, JP | 1 |
| Costermans, J | 1 |
| Verberckmoes, R | 1 |
| Harvengt, C | 1 |
| Hottelart, C | 1 |
| el Esper, N | 1 |
| Achard, JM | 1 |
| Pruna, A | 1 |
| Fournier, A | 1 |
| Landray, MJ | 1 |
| Townend, JN | 1 |
| Martin, S | 1 |
| Martin, U | 1 |
| Wheeler, DC | 1 |
| Levin, A | 1 |
| Duncan, L | 1 |
| Djurdjev, O | 1 |
| Shapiro, RJ | 1 |
| Frohlich, J | 1 |
| Belanger, A | 1 |
| Dumas, R | 1 |
| Ross, S | 1 |
| Chapman, MJ | 1 |
3 reviews available for fenofibrate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hy | 2018 |
Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dys | 2008 |
Pharmacology of fenofibrate.
Topics: Biological Transport; Fenofibrate; Food; Half-Life; Humans; Intestinal Absorption; Kidney; Kidney Fa | 1987 |
4 trials available for fenofibrate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Ty | 2018 |
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glomerular Filtration | 2012 |
[Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency].
Topics: Aged; Creatinine; Cross-Over Studies; Female; Fenofibrate; Glomerular Filtration Rate; Humans; Hyper | 1999 |
A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate.
Topics: Adult; Aged; Combined Modality Therapy; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipid | 2000 |
8 other studies available for fenofibrate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Fenofibrate Delays the Need for Dialysis and Reduces Cardiovascular Risk Among Patients With Advanced CKD.
Topics: Adult; Aged; Cardiovascular Diseases; Cohort Studies; Disease Progression; Female; Fenofibrate; Hear | 2021 |
Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Fenofibrate; Humans; Hypolipidemic Agent | 2012 |
Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation.
Topics: Adolescent; Adult; Aged; Apolipoprotein E2; Biomarkers; Biopsy; Case-Control Studies; China; Creatin | 2014 |
Long-term use of fenofibrate is associated with increased prevalence of gallstone disease among patients undergoing maintenance hemodialysis.
Topics: Aged; Cross-Sectional Studies; Female; Fenofibrate; Gallstones; Humans; Hypolipidemic Agents; Kidney | 2011 |
Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report.
Topics: Adult; Fatigue; Fenofibrate; Humans; Hypertension; Hypoalbuminemia; Hypolipidemic Agents; Kidney Fai | 2012 |
Elevation of CKP induced by ezetimibe in monotherapy: report on two cases.
Topics: Anticholesteremic Agents; Azetidines; Creatine Kinase; Creatinine; Diabetes Mellitus, Type 2; Ezetim | 2006 |
Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure.
Topics: Adult; Aged; Female; Fenofibrate; Humans; Kidney Failure, Chronic; Kinetics; Male; Middle Aged; Prop | 1982 |
Lipid-lowering drugs and homocysteine.
Topics: Fenofibrate; Homocysteine; Humans; Hypolipidemic Agents; Kidney Failure, Chronic; Middle Aged | 1999 |